Common Contracts
30 similar null contracts by Merus N.V., Omnicom Group Inc., Lexicon Pharmaceuticals, Inc., others
APi Group Corporation 10,569,106 Shares Common Stock ($0.0001 par value) Underwriting AgreementAPi Group Corp • March 5th, 2024 • Construction - special trade contractors • New York
This letter is being delivered to you in connection with the proposed underwriting agreement (the “Underwriting Agreement”), between APi Group Corporation, a Delaware corporation (the “Company”), and you as representatives of a group of Underwriters named therein, relating to an underwritten public offering of Common Stock, $0.0001 par value (the “Common Stock”), of the Company (the “Offering”).
Merus N.V. 6,818,182 Common Shares (nominal value €0.09 per share) Underwriting AgreementMerus N.V. • August 11th, 2023 • Pharmaceutical preparations • New York
Merus N.V., a public limited liability company incorporated under the laws of the Netherlands (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 6,818,182 common shares in the share capital of the Company, nominal value €0.09 per share (the “Common Shares”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 1,022,727 additional Common Shares (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as t
LEXICON PHARMACEUTICALS, INC. 23,924,705 Shares Common Stock ($0.001 par value) Underwriting AgreementLexicon Pharmaceuticals, Inc. • June 2nd, 2023 • Pharmaceutical preparations • New York
LEXICON PHARMACEUTICALS, INC. 16,843,600 Shares Common Stock ($0.001 par value) Underwriting AgreementLexicon Pharmaceuticals, Inc. • July 29th, 2022 • Pharmaceutical preparations • New York
Primerica, Inc. Underwriting AgreementPrimerica, Inc. • November 19th, 2021 • Life insurance • New York
Primerica, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the principal amount of its securities identified in Schedule I hereto (the “Securities”), to be issued under an indenture (the “Base Indenture”) dated as of July 16, 2012, between the Company and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National Association, as trustee (the “Trustee”), as supplemented by the second supplemental indenture thereto to be dated as of November 19, 2021, between the Company and the Trustee (the “Supplemental Indenture” and, together with the Base Indenture, the “Indenture”). Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Final Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pur
Merus N.V. 3,859,650 Common Shares (nominal value €0.09 per share) Underwriting AgreementMerus N.V. • November 8th, 2021 • Pharmaceutical preparations • New York
Underwriting AgreementOmnicom Group Inc. • May 3rd, 2021 • Services-advertising agencies • New York
Omnicom Group Inc., a New York corporation, (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the principal amount of its 2.600% Senior Notes due 2031 (the “Securities”) identified in Schedule II hereto, to be issued under an indenture dated as of the Closing Date (as defined herein) (the “Base Indenture”), between the Company and Deutsche Bank Trust Company Americas, a New York banking corporation, as trustee (the “Trustee”), as supplemented by the Third Supplemental Indenture to be dated as of the Closing Date, between the Company and the Trustee (the “Supplemental Indenture”). The Supplemental Indenture together with the Base Indenture are herein collectively referred to as the “Indenture.”
PhaseBio Pharmaceuticals, Inc. 16,000,000 Shares Common Stock ($0.001 par value) Underwriting AgreementPhaseBio Pharmaceuticals Inc • March 19th, 2021 • Pharmaceutical preparations • New York
Cohu, Inc. 4,950,000 Shares Common Stock ($1.00 par value) Underwriting AgreementCohu Inc • March 4th, 2021 • Instruments for meas & testing of electricity & elec signals • New York
This letter is being delivered to you in connection with the proposed underwriting agreement (the “Underwriting Agreement”), between Cohu, Inc., a Delaware corporation (the “Company”), and each of you as representatives (together, the “Representatives”) of a group of underwriters (the “Underwriters”) named therein, relating to an underwritten public offering of Common Stock, $1.00 par value (the “Common Stock”), of the Company (the “Offering”).
Merus N.V. 4,848,485 Common Shares (nominal value €0.09 per share) Underwriting AgreementMerus N.V. • January 22nd, 2021 • Pharmaceutical preparations • New York
Merus N.V., a public limited liability company incorporated under the laws of the Netherlands (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 4,848,485 common shares in the share capital of the Company, nominal value €0.09 per share (the “Common Shares”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 727,272 additional Common Shares (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the
Commercial Metals Company Underwriting AgreementCOMMERCIAL METALS Co • January 21st, 2021 • Steel works, blast furnaces & rolling mills (coke ovens) • New York
Commercial Metals Company, a corporation organized under the laws of Delaware (the “Company”), proposes to issue and sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, $300,000,000 in aggregate principal amount of its 3.875% Senior Notes due 2031, as set forth on Schedule I hereto (the “Securities”), to be issued under an indenture (the “Base Indenture”), dated as of May 6, 2013, between the Company and U.S. Bank National Association, as trustee (the “Trustee”), as supplemented by a supplemental indenture, to be dated as of February 2, 2021 (the “Supplemental Indenture” and together with the Base Indenture, the “Indenture”). Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Final Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 which were filed under
STANLEY BLACK & DECKER, INC. $750,000,000 2.750% Notes due 2050 Underwriting AgreementStanley Black & Decker, Inc. • November 2nd, 2020 • Cutlery, handtools & general hardware • New York
OPTHEA LIMITED [●] American Depositary Shares Representing [●] Ordinary Shares (no par value) Underwriting AgreementOpthea LTD • October 9th, 2020 • Biological products, (no disgnostic substances) • New York
TRANSLATE BIO, INC. 12,506,811 Shares of Common Stock, par value $0.001 per share Underwriting AgreementTranslate Bio, Inc. • June 26th, 2020 • Biological products, (no disgnostic substances) • New York
NO PAR VALUE) Underwriting AgreementPACIFIC GAS & ELECTRIC Co • June 26th, 2020 • Electric & other services combined • New York
PG&E Corporation, a corporation organized under the laws of the State of California (the “Company”), confirms its agreement (this “Agreement”) with each of the Underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as Representatives, with respect to the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of 423,372,629 shares of common stock, no par value, of the Company (the “Common Stock”). The aforesaid 423,372,629 shares of Common Stock to be purchased by the Underwriters are hereinafter called the “Underwritten Securities.” The Company also proposes to grant to the Underwriters an option to purchase up to 42,337,263 additional shares of Common Stock. The aforesaid 42,337,263 additional shares of Common Stock that may be purchased by the Underwriters are hereinafter called the “Option Securities” and, together with the Underwritten Securities, are hereinafter called the “Securities.” Any
Omnicom Group Inc. Underwriting AgreementOmnicom Group Inc. • April 1st, 2020 • Services-advertising agencies • New York
Omnicom Group Inc., a New York corporation, (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the principal amount of its 4.200% Senior Notes due 2030 (the “Securities”) identified in Schedule II hereto, to be issued under an indenture dated as of the Closing Date (as defined herein) (the “Base Indenture”), between the Company and Deutsche Bank Trust Company Americas, a New York banking corporation, as trustee (the “Trustee”), as supplemented by the Second Supplemental Indenture to be dated as of the Closing Date, between the Company and the Trustee (the “Supplemental Indenture”). The Supplemental Indenture together with the Base Indenture are herein collectively referred to as the “Indenture.”
Omnicom Group Inc. Underwriting AgreementOmnicom Group Inc. • February 21st, 2020 • Services-advertising agencies • New York
Omnicom Group Inc., a New York corporation, (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the principal amount of its 2.450% Senior Notes due 2030 (the “Securities”) identified in Schedule II hereto, to be issued under an indenture dated as of the Closing Date (as defined herein) (the “Base Indenture”), between the Company and Deutsche Bank Trust Company Americas, a New York banking corporation, as trustee (the “Trustee”), as supplemented by the First Supplemental Indenture to be dated as of the Closing Date, between the Company and the Trustee (the “Supplemental Indenture”). The Supplemental Indenture together with the Base Indenture are herein collectively referred to as the “Indenture.”
STANLEY BLACK & DECKER, INC. $500,000,000 3.400% Notes Due 2026 Underwriting AgreementStanley Black & Decker, Inc. • March 1st, 2019 • Cutlery, handtools & general hardware • New York
VANDA PHARMACEUTICALS INC. 5,500,000 Shares 1 Common Stock ($0.001 par value) Underwriting AgreementVanda Pharmaceuticals Inc. • March 16th, 2018 • Pharmaceutical preparations • New York
Vanda Pharmaceuticals Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.001 par value (“Common Stock”), of the Company set forth in Schedule I hereto (the “Securities”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Un
Arcus Biosciences, Inc. [●] Shares Common Stock ($0.0001 par value per share) Underwriting AgreementArcus Biosciences, Inc. • March 5th, 2018 • Pharmaceutical preparations • New York
National Vision Holdings, Inc. [●] Shares Common Stock ($0.01 par value) Underwriting AgreementNational Vision Holdings, Inc. • October 16th, 2017 • Ophthalmic goods • New York
National Vision Holdings, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [●] shares of common stock, $0.01 par value (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [●] additional shares of Common Stock to cover overallotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). Certain terms used herein are defined in Section 21 hereof.
Commercial Metals Company Underwriting AgreementCommercial Metals Co • June 30th, 2017 • Steel works, blast furnaces & rolling mills (coke ovens) • New York
Commercial Metals Company, a corporation organized under the laws of Delaware (the “Company”), proposes to issue and sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, $300,000,000 in aggregate principal amount of its 5.375% Senior Notes due 2027, as set forth on Schedule I hereto (the “Securities”), to be issued under an indenture (the “Base Indenture”), dated as of May 6, 2013, between the Company and U.S. Bank National Association, as trustee (the “Trustee”), as supplemented by a supplemental indenture, to be dated as of July 11, 2017 (the “Supplemental Indenture” and together with the Base Indenture, the “Indenture”). Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Final Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 which were filed under the
Oncobiologics, Inc. [________] Units 1 Each Unit Consisting of One Share of Common Stock ($0.01 par value), One Half of a Series A Warrant to purchase One Share of Common Stock and One Half of a Series B Warrant to purchase One Share of Common Stock...Oncobiologics, Inc. • May 11th, 2016 • Biological products, (no disgnostic substances) • New York
AmSurg Corp. 5,500,000 Shares Common Stock (no par value) Underwriting AgreementAmsurg Corp • December 7th, 2015 • Services-offices & clinics of doctors of medicine • New York
AmSurg Corp., a corporation organized under the laws of Tennessee (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, no par value (“Common Stock”), of the Company set forth in Schedule I hereto (the “Securities”) (said shares to be issued and sold by the Company being hereinafter called the “Firm Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto (the “Option Securities”; the Option Securities, together with the Firm Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the s
The Valspar Corporation $350,000,000 3.950% Notes due 2026 Underwriting AgreementValspar Corp • July 28th, 2015 • Paints, varnishes, lacquers, enamels & allied prods • New York
* Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.
Kindred Healthcare, Inc. 9,000,000 Shares Common Stock ($0.25 par value) plus an option to purchase from the Company up to 1,350,000 additional shares of Common Stock Underwriting AgreementKindred Healthcare, Inc • June 25th, 2014 • Services-nursing & personal care facilities • New York
Kindred Healthcare, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule III hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.25 par value (“Common Stock”), of the Company set forth in Schedule I hereto (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule III hereto (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule III other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall m
Ampio Pharmaceuticals, Inc. 8,500,000 Shares Common Stock ($0.0001 par value) plus an option to purchase from the Company up to 1,275,000 additional Shares of Common Stock Underwriting AgreementAmpio Pharmaceuticals, Inc. • February 28th, 2014 • Pharmaceutical preparations • New York
Ampio Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $.0001 par value (“Common Stock”), of the Company set forth in Schedule I hereto (said shares to be issued and sold by the Company collectively being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”).
Common Stock ($0.001 par value) Underwriting AgreementEleven Biotherapeutics, Inc. • January 23rd, 2014 • Pharmaceutical preparations • New York
Eleven Biotherapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, shares of common stock, $0.001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the conte
Primerica Inc. 12,000,000 Shares1 Common Stock ($0.01 par value) Underwriting AgreementPrimerica, Inc. • April 15th, 2011 • Life insurance • New York
Citigroup Insurance Holding Corporation, a corporation organized under the laws of the State of Georgia (“CIHC”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representative”) are acting as Representative, 12,000,000 shares of common stock, $0.01 par value (“Common Stock”) of Primerica, Inc., a corporation organized under the laws of the State of Delaware (the “Company”) (said shares to be sold by CIHC, collectively, being hereinafter called the “Underwritten Securities”). CIHC also proposes to grant to the Underwriters an option to purchase up to 1,800,000 additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representative as used herein shall mean you, as Underwriters, and t
6,325,000 Ordinary Shares ($.01 par value) Underwriting AgreementApex Silver Mines LTD • August 9th, 2006 • Gold and silver ores • New York
Apex Silver Mines Limited, a Cayman Islands company (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representative”) are acting as representative, 6,325,000 Ordinary Shares, $.01 per share par value (“Ordinary Shares”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representative as used herein shall mean you, as Underwriter, and the terms Representative and Underwriters shall mean either the singular or plural as the context requires. The use of the neuter in this Agreement shall include the feminine and masculine wherever appropriate. Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Final Prospectus shall be deemed to refer to and include the documents incorporated by reference therein purs
